Type 1 diabetes: Tannic acid encapsulation protects transplanted islets from rejection

Transplanting cadaver pancreatic islets is a promising therapy for Type 1 diabetes, but a reactivated autoimmunity means low graft viability after five years. Research now shows that a protective coating of two biopolymers can delay allograft and autoimmune-mediated rejection in mouse models of T1D.

Read more

15-Year Trend Persists in Disparate Insulin Pump Use in Children

Insulin pumps are widely used in the management of type 1 diabetes (T1D) and reviews have shown insulin pump therapy to be associated with improved glycemic control, fewer severe hypoglycemia events, and improved quality of life. Yet, non-Hispanic white children (NHW) are more than twice as likely as non-Hispanic Black children (NHB) to use this technology.

Read more

Complications from diabetes linked to worse memory, IQ in children

A study led by UC Davis Health researchers uncovered that even one severe episode of diabetic ketoacidosis (DKA) in children newly diagnosed with type 1 diabetes is linked to cognitive problems; and among children with a previous diagnosis, repeated DKA exposure predicted lower cognitive performance after accounting for glycemic control.

Read more

Helping Teens with Type 1 Diabetes Improve Diabetes Control with MyDiaText

Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM). The challenges of managing multiple doses of daily insulin administration, blood glucose monitoring, dietary and exercise requirements, can make self-care difficult and complicate outcomes. Adolescents with T1DM often have poorer diabetes outcomes than others, indicating that glucose control is difficult for them to maintain.

Read more

Novel diabetes drug candidate shows promising properties in human islets and mouse models

Researchers have discovered a new drug candidate that offers a major advance to treat diabetes. Tested on human and mouse pancreatic islets, mouse and rat cell cultures and animal models of Type 1 and Type 2 diabetes, the drug significantly improved four detrimental characteristics of diabetes.

Read more

NIH Awards $9.5 Million for Einstein-Mount Sinai Diabetes Research Center

Albert Einstein College of Medicine has received a $9.5 million, five-year grant from the National Institutes of Health (NIH) to support the Einstein-Mount Sinai Diabetes Research Center (ES-DRC). The multi-institutional center is a leader in basic, translational, clinical, and community-based research and training in type 1 and type 2 diabetes, obesity, and other metabolic disorders.

Read more